599 related articles for article (PubMed ID: 17157662)
1. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
2. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis.
Bullock JZ; Villanueva JM; Blanchard C; Filipovich AH; Putnam PE; Collins MH; Risma KA; Akers RM; Kirby CL; Buckmeier BK; Assa'ad AH; Hogan SP; Rothenberg ME
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):22-31. PubMed ID: 17592361
[TBL] [Abstract][Full Text] [Related]
3. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
5. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.
Lucendo AJ; De Rezende L; Comas C; Caballero T; Bellón T
Am J Gastroenterol; 2008 Sep; 103(9):2184-93. PubMed ID: 18844613
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.
Konikoff MR; Noel RJ; Blanchard C; Kirby C; Jameson SC; Buckmeier BK; Akers R; Cohen MB; Collins MH; Assa'ad AH; Aceves SS; Putnam PE; Rothenberg ME
Gastroenterology; 2006 Nov; 131(5):1381-91. PubMed ID: 17101314
[TBL] [Abstract][Full Text] [Related]
7. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis.
Sayej WN; Patel R; Baker RD; Tron E; Baker SS
J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):393-9. PubMed ID: 19633574
[TBL] [Abstract][Full Text] [Related]
8. Esophageal subepithelial fibrosis in children with eosinophilic esophagitis.
Chehade M; Sampson HA; Morotti RA; Magid MS
J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):319-28. PubMed ID: 17873744
[TBL] [Abstract][Full Text] [Related]
9. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.
Blanchard C; Mingler MK; Vicario M; Abonia JP; Wu YY; Lu TX; Collins MH; Putnam PE; Wells SI; Rothenberg ME
J Allergy Clin Immunol; 2007 Dec; 120(6):1292-300. PubMed ID: 18073124
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.
Bhattacharya B; Carlsten J; Sabo E; Kethu S; Meitner P; Tavares R; Jakate S; Mangray S; Aswad B; Resnick MB
Hum Pathol; 2007 Dec; 38(12):1744-53. PubMed ID: 17900656
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
12. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R; Newbury R; Fox L; Bastian J; Aceves S
Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
[TBL] [Abstract][Full Text] [Related]
13. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis.
Konikoff MR; Blanchard C; Kirby C; Buckmeier BK; Cohen MB; Heubi JE; Putnam PE; Rothenberg ME
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1328-36. PubMed ID: 17059896
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis.
Gonsalves N; Policarpio-Nicolas M; Zhang Q; Rao MS; Hirano I
Gastrointest Endosc; 2006 Sep; 64(3):313-9. PubMed ID: 16923475
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus.
Lucendo AJ; Navarro M; Comas C; Pascual JM; Burgos E; Santamaría L; Larrauri J
Am J Surg Pathol; 2007 Apr; 31(4):598-606. PubMed ID: 17414108
[TBL] [Abstract][Full Text] [Related]
16. Current concepts and treatment options in eosinophilic esophagitis.
Pasha SF; Sharma VK; Crowell MD
Curr Opin Investig Drugs; 2006 Nov; 7(11):992-6. PubMed ID: 17117587
[TBL] [Abstract][Full Text] [Related]
17. Esophageal remodeling in pediatric eosinophilic esophagitis.
Aceves SS; Newbury RO; Dohil R; Bastian JF; Broide DH
J Allergy Clin Immunol; 2007 Jan; 119(1):206-12. PubMed ID: 17208603
[TBL] [Abstract][Full Text] [Related]
18. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
19. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults.
Rodrigo S; Abboud G; Oh D; DeMeester SR; Hagen J; Lipham J; DeMeester TR; Chandrasoma P
Am J Gastroenterol; 2008 Feb; 103(2):435-42. PubMed ID: 18289205
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.
Park CW; Lee BH; Han HJ; Lee CH; Ahn HK
Br J Dermatol; 2005 Jun; 152(6):1173-81. PubMed ID: 15948978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
